Interpace Diagnostics Reports Second Quarter 2017 Financial Results, Business Progress And Recent Accomplishments

Published: Aug 10, 2017

PARSIPPANY, N.J., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced financial results and business progress for the second quarter ended June 30, 2017 and year to date, as well as recent accomplishments.

“The second quarter and year to date in 2017 was certainly transformative for Interpace. We continued to improve our balance sheet in the second quarter by raising an additional $13.7 million of capital, eliminating all long term debt and related possible royalties and milestone obligations while continuing to make good commercial progress,” said Jack Stover, Interpace’s President & CEO.

Back to news